Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To examine the efficacy and safety of treatment with desvenlafaxine for vascular depression.
Primary efficacy, as it pertains to depressive symptoms, will be assessed by overall change
in symptom severity score from baseline to 12-weeks, measured by the Geriatric Depression
Scale. The primary efficacy measure of cognition will be the Montreal Cognitive Assessment
and analysis of change between baseline and 12-week scores.
To evaluate the effectiveness of desvenlafaxine as a first-line treatment for vascular
depression in a sub-group of patients who have experienced a TIA greater than 6 weeks prior
to baseline. Mean differences between baseline and 12-week efficacy measures will be examined
within the sub-group.